Medical Device Deals Update, March 2012
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
You may also be interested in...
Bills to narrow the Medicare price negotiation program’s reach generated extensive discussion at the hearing.
The FDA commissioner also does not want the agency setting goals for rare disease treatment development.
Aggressive staffing goals for FDA’s gene and cell therapy review group might not be fully achieved – but the head of CBER believes the new organization is on track to deliver on his high expectations going forward.